Actively Recruiting
Selection of Resistant Mutations to Dolutegravir in PLWH Treated in Mozambique
Led by Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · Updated on 2025-05-15
200
Participants Needed
1
Research Sites
96 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The HIV infection not fully controlled, despite being under antiretroviral treatment, could make virus resistance against the antiretroviral treatments, making hardest the well control of HIV infection. The purpose of this research study is to confirm or deny if a not fully good controlled HIV infection could develop virus resistance against antiretroviral drugs that can difficult the good control of the HIV infection.
CONDITIONS
Official Title
Selection of Resistant Mutations to Dolutegravir in PLWH Treated in Mozambique
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to understand and sign the informed consent form
- Documented HIV-1 infection
- Receiving first-line TLD treatment for at least 6 months
- At least 3 months follow-up with viral load over 200 copies/ml
You will not qualify if you...
- Under 18 years of age
- Receiving first-line regimen other than TLD
- Having active cancer or neoplastic diseases
- Having active opportunistic infections
- Unable to give informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital Carmelo
Chokwé, Mozambique, F2C3+JPR
Actively Recruiting
Research Team
D
Daniel Podzamczer, PhD
CONTACT
A
Antonio Navarro, MSc
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here